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gluconeogenesis and cholesterol metabolism. However, over the
last decades, a variety of pathological conditions highlighted the
importance of metabolic functions within the diseased liver. As
observed in Western societies, an increase in the prevalence of
obesity and themetabolic syndrome promotes pathophysiological
changes that cause non-alcoholic fatty liver disease (NAFLD).
NAFLD increases the susceptibility of the liver to acute liver injury
andmay lead to cirrhosis and hepatocellular cancer. Alterations in
insulin response, b-oxidation, lipid storage and transport,Journal of Hepatology 20
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receptor; VLDL, very low-density lipoproteins.signaling are held accountable for these changes. Furthermore,
recent studies revealed a role for lipid accumulation in inﬂamma-
tion and ER stress in the clinical context of liver regeneration and
hepatic carcinogenesis. This review focuses on novel ﬁndings
related to nuclear receptor signaling – including the vitamin D
receptor and the liver receptor homolog 1 – in hepatic lipid and
glucose uptake, storage and metabolism in the clinical context of
NAFLD, liver regeneration, and cancer.
 2012 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Key Points 1
• The prevalence of obesity and the metabolic syndrome 
is rising dramatically
• Obesity and the metabolic syndrome promote alterations 
in hepatic lipid and glucose metabolism and are linked to 
the pathophysiologies of NAFLD and liver cancer
• Lipid accumulation and fatty acid oxidation are important 
mechanisms in liver damage, repair and regeneration, 
partially due to induction of autophagy and ROS 
production
• Insulin and nuclear receptor (including PPAR, LXR, 
FXR, LRH1 and vitamin D receptor) signaling regulate 
hepatic lipid and glucose metabolism, and are closely 
interrelated
• Both metabolic pathways share common regulatory 
elements as well as metabolites and indistinguishably 
contribute to NAFLD, liver cancer, and liver regenerationIntroduction
As the main detoxifying organ of the body, the liver also plays a
central role in metabolic homeostasis and is a major site for syn-
thesis, metabolism, storage and redistribution of carbohydrates,12 vol. 56 j 952–964
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proteins and lipids. The rapid increase in obesity worldwide is
associatedwith an increase in theprevalence of non-alcoholic fatty
liver disease (NAFLD), making NAFLD the most common liver
disease in Western societies [1,2]. In order to understand the
pathogenesis of NAFLD, we discuss the basic physiologic
mechanisms of hepatic lipid and glucose metabolism. We also
aimed at integrating recent clinical andmechanistic data and point
out novel links between basic metabolic pathways and the patho-
physiologies of NAFLD, liver regeneration, and carcinogenesis.
NAFLD is characterized by lipid accumulation within hepato-
cytes and may progress to non-alcoholic steatohepatitis (NASH).
Lipids derive from circulating fatty acids (FA) upon insulin resis-
tance (IR)-induced dysregulation of peripheral lipolysis. FAs are
translocated into the hepatocyte mainly by membrane bound
transport proteins [3]. De novo lipogenesis (DNL) further contrib-
utes to hepatic steatosis [4]. Hepatocellular accumulation of lipo-
toxic intermediates such as diacylglycerol (DAG) and ceramids
causes hepatic IR [5]. Hepatocytic lipid accumulation predisposes
to overproduction of reactive oxygen species (ROS), endoplasmatic
reticulum (ER) stress and lipotoxicity [6–8]. Recently, autophagy
(especially in the form of macrolipophagy) has been identiﬁed to
regulate intracellular lipid stores through degradation of lipid
droplets and release of FAs into the cytosol as a rapid response to
starvation [9–11]. Thus, disrupted autophagy might be essential
to thepathogenesis ofNASHvia lipotoxicity-inducedERstress [12].
The individual steps in hepatic lipid metabolism are orches-
trated by a delicate interplay of hormones, nuclear receptors,
intracellular signaling pathways and transcription factors. Insulin
signaling plays an important role in the regulation of FA metab-
olism, underscoring the close relation between lipid and glucose
metabolism. Insulin affects DNL on multiple levels, via induction
of lipogenic genes, activation of sterol-response-binding-protein-
1c (SREBP-1c) and Akt-regulated production of very low-density
lipoproteins (VLDLs) [13]. Insulin, along with other mediators
(e.g., calpain-1), further represses autophagy within the hepato-
cyte, and thus induces lipogenesis and represses lipid-degrada-
tion in the fed state as well [9,12]. On the other hand,
glucagon-like peptide-1 (GLP-1) also alters hepatic lipid metabo-
lism [14]. FA oxidation and the expression of fatty acid transport
proteins (FATPs) are closely regulated by the nuclear receptor
peroxisome proliferator-activated receptor (PPAR)a, and in the
steatotic liver also by PPARc [15].
In the following paragraphs, we will discuss the function of
hepatic lipid and glucose metabolism under normal conditions
and their roles inNAFLD, acute liver injury and regenerationaswell
as hepatic carcinogenesis. This review focuses on the central role of
nuclear receptor signaling in hepatic glucose and lipidmetabolism
including novel mechanisms like vitamin D receptor (VDR) and
liver receptor homolog 1 (LRH1) signaling, autophagy and the
interrelation of ER stress and metabolism Table 1.Hepatic lipid metabolism
Extrahepatic lipid metabolism
Lipid metabolism starts with the intestinal absorption of dietary
fats. In order to cross the intestinal lumen into the plasma, lipids
are emulsiﬁed and hydrolyzed within the lumen. The healthy
liver is crucial for intestinal lipid absorption via bile acids (BA)
that are synthesized within the hepatocyte and secreted intoJournal of Hepatology 201the bile duct to emulsify lipid droplets by their amphiphilic prop-
erties rendering them accessible to lipase hydrolyzation. Hydro-
lyzed lipids are then absorbed by enterocytes, where lipids are
re-synthesized and packed into lipoprotein particles (i.e., nascent
chylomicrons).
Nascent chylomicrons are secreted into the lymphatic system,
where they bypass the liver and enter the circulation within two
hours after food intake [16]. During their journey through the
vascular system, nascent chylomicrones lose two minor apopro-
teins (apoA-I and apoA-IV), which are replaced by apoE and
apoC-II that are crucial for their further processing. ApoC-II acti-
vates adipocyte lipoprotein lipase (LPL), which facilitates the
digestion of the chylomicron triacylglycerols (TAGs) into FAs
and glycerol [17]. FAs are then partially taken up and stored in
adipocytes, while chylomicron remnants re-enter the blood
stream. ApoE is then recognized by the hepatocyte LDL receptor,
the LDL receptor-related protein (LRP) and scavenger receptor
B-1, which facilitate endocytotic uptake of the chylomicron rem-
nants. As cholesteryl-ester enriched and triglyceride-depleted
products of chylomicron metabolism, chylomicron remnants are
ﬁnally processed by intracellular lysosomes – and their glycerol,
FA, cholesterol, amino acid and phosphate residues are metabo-
lized and recycled into new VLDLs (see Fig. 1A for overview).
Hepatic lipogenesis
As mentioned above, hepatic FAs either derive from endogenous
lipogenesis, are released from lysosomes by autophagy, or derive
from the free FA (FFA) plasma pool via active uptake into the
hepatocyte. Depending on the metabolic state, FAs are then either
processed to TAGs and stored or rapidly metabolized. Indeed,
b-oxidation is the predominant source of energy during the fast-
ing state.
Hepatic lipogenesis includes de novo synthesis of FAs from
acetyl-CoA or malonyl-CoA and further processing to TAGs. In
mammals, FA synthesis is catalyzed by acetyl-CoA carboxylase
(ACC) and fatty acid synthase (FAS) – an enzyme that is com-
plexly regulated by various nuclear receptors (PPARa, PPARc
and the bile acid receptor/farnesoid X receptor [FXR]) [18–20].
FA elongation requires NADPH as a reducing reagent, which is
provided by the pentose phosphate pathway (Fig. 2B). Remark-
ably, PPARa itself is activated by a phospholipid synthesized by
FAS, indicating a feedback loop [21].
A close link between glucose and lipid metabolism is indi-
cated by the fact that nuclear receptors (NRs) are also important
mediators of insulin signaling and since DNL occurs under ana-
bolic condition. The existence of such a link is further supported
by the fact that insulin stimulates FAS expression via the phos-
phoinositide-3-kinase (PI3K) pathway [22]. On a transcriptional
level, SREBP-1c and carbohydrate-responsive element binding
protein (ChREBP), a glucose dependant transcription factor, syn-
ergistically induce expression of FAS and ACC [23].
As FAs and their metabolites are the major cause for lipotox-
icity and promote the formation of ROS, FAs are stored for future
use as TAGs, which are relatively inert and consist of three FAs
esteriﬁed to a glycerol backbone. TAGs are then either stored in
lipid droplets within the hepatocyte or processed to VLDL [7].
TAG synthesis is catalyzed by the enzymes mitochondrial glyc-
erol-3-phosphate-acyltransferase (mtGPAT) and diacylglycerol-
acyltransferase (DGAT) [24]. TAGs are then packaged into VLDL
particles, by conjugation to apoB-100 in a 5:1 TAG/cholesterol2 vol. 56 j 952–964 953
Table 1. Overview of ligands and function of the most abundant nuclear receptors in hepatocytes.
Nuclear 
receptor
Natural ligands Chemical 
ligands/
agonists
Function in lipid 
metabolism
Function in glucose 
metabolism
Role in NAFLD Role in liver 
regeneration
Role in HCC
PPARα Fatty acids Fibrates Regulates expression of 
FAS        lipogenesis;
CD36/FAT, 
FATPs        FA-Uptake;
Acetyl-CoA-synthetase, 
CPT-1        β-oxidation
Regulates PEPCK, 
GSK3, 
Glycogen synthase  
        glycogen
metabolism; 
insulin sensitivity
Fibrate treatment 
improves IR
Delayed 
regeneration in 
PPARα KO mice
PPARα activation 
is associated with 
liver carcinogenesis
PPARγ Prostaglandins Glitazones Regulates expression of 
CD36/FAT       FA-Uptake; 
SCD-1       FA-metabolism
Regulates GLUT-4   
expression       
insulin sensitivity
Activation;
PPARγ KO mice 
are protected 
from diet induced 
steatosis; 
Glitazones 
improve IR and 
TAG accumulation 
and increase 
adiponectin levels
Downregulated; 
glitazones inhibit 
hepatocyte 
proliferation
PPARγ KO 
increases 
susceptibility 
to hepatic 
carcinogens; 
PPARγ activation 
induces cell cycle 
arrest in hepatoma 
cells
PPARδ Fatty acids Glitazones;
GW501516
Regulates SREBP-1c     
lipogenesis
Induces glycolysis 
and pentose 
phosphate 
pathway shunt
Agonist treatment 
improves hepatic 
steatosis in mice
Agonist treatment 
improves liver 
regeneration in mice
PPARδ affects 
COX2 expression in 
hepatomas
FXR Bile acids Chenodeoxy-
cholic acid 
(CDCA);
GW4064
Regulates SREBP-1c 
lipogenesis;
Regulates VLDL formation 
via SHP
Regulates 
PEPCK, glucose-
6-phosphatase       
gluconeogenesis
Induced; 
SHP is 
upregulated in 
NAFLD; 
FXR KO mice 
develop steatosis
Mediates liver 
regeneration after 
partial hepatectomy; 
impaired 
regeneratory 
capacity in FXR KO 
mice
FXR KO mice 
develop hepatic 
tumors; interaction 
with Wnt/β-catenin 
signaling
Downstream target 
SHP reduced in 
human HCC
LXRα Hydroxysterols T0901317;
GW3965
Regulates SREBP-
1c, SCD-1, FAS        
lipogenesis; cholesterol 
metabolism
Regulates 
insulin receptor 
expression, 
GLUT-4 and 
IRS expression      
insulin sensitivity
Induced, LXR 
promotes hepatic 
lipogenesis
Reduced activation 
after partial 
hepatectomy
Unknown
VDR (1),25-Hydroxy-
vitamin D3
Calcitriol-
derivates
VDR represses PPARα 
signaling, direct effects 
unknown
VDR represses 
PPARα signaling, 
direct effects 
unknown
Downregulated; 
VDR KO mice 
develop steatosis; 
vitamin D protects 
from diet induced 
steatosis
leads to impaired 
hepatic regeneration
VDR 
polymorphisms are 
associated with 
HCC
LRH1 Phospholipids Dilauroyl 
phosphatidyl-
choline (DLPC)
Repression of SHP       
potential effects on 
VLDL synthesis; DLPC 
treatment suppresses 
SREBP-1c, FAS, ACC-2 
and SCD-1 expression 
in vivo
DLPC treatment 
reduces hepatic 
gluconeogenesis 
and improves 
insulin response 
in vivo
DLPC treatment 
improves hepatic 
TAG and FA 
accumulation
Unknown; 
potential proliferative 
effects
Unknown; 
repression of SHP 
might promote 
tumor growth
Vitamin D deficiency
Reviewratio. These processes are controlled by SREBP-1c, the liver X
receptor (LXR), FXR and ChREBP, which again links glucose and
lipid metabolism [25].
Hepatic fatty acid uptake
Another source for hepatic FAs is FFA recruitment from the
plasma pool. FFAs are derived from lipolysis in adipocytes. This
occurs usually in the fasting state, where it is promoted by cate-
cholamines, natriuretic peptides and glucagon, while it is usually
repressed by insulin [26]. However, the insulin-resistant state
(obesity; metabolic syndrome) goes along with increased
adipocyte lipolysis, leading to abundant FFAs in the plasma pool
independently from the nutritional status [27]. FFAs are then954 Journal of Hepatology 201taken up by the hepatocytes in a facilitated fashion rather than
by passive processes [28]. FATPs are thus in the focus of NAFLD
research in which a variety of FATPs have been identiﬁed. While
FATP1 is abundant in muscle and adipose tissue and is barely
detectable in the liver [29], FATP2 and FATP5 are expressed in
hepatocytes and most likely facilitate the major amount of FA
uptake in the liver [30]. Other transport proteins include fatty
acid binding protein (FABP), glutamate–oxaloacetate-transami-
nase 2 (Got2; or mitochondrial aspartate aminotransferase [mAs-
pAT], a membrane bound protein that mediates the endocytotic
uptake of long-chain FAs), and caveolin-1 [31–33]. Fatty acid
translocase (CD36/FAT) is a membrane glycoprotein present on
platelets, mononuclear phagocytes, adipocytes and hepatocytes
with multiple functions, including thrombospondin-1 receptor2 vol. 56 j 952–964
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Fig. 1. Hepatic lipid metabolism in health and disease. (A) Dietary lipids are emulsiﬁed in the intestinal tract by bile acids (BAs). Hydrolyzed lipids are absorbed by
enterocytes and packed into nascent chylomicrons (NCs). NCs enter the bloodstream via the thoracic ductwhere they receive important apoproteins (apoE; apoC-II) fromHDL.
These apoproteins are important for chylomicrons (C) to deliver TAGs and FAs to adipocytes andmyocytes via lipoprotein lipase (LPL) degradation. Chylomicron remnants are
taken up by hepatocytes via LDL-receptor (LDLR) and LDL receptor-related protein (LRP)-mediated endocytosis. BA synthesis is regulated by LRH1 and FXR, which activate BA
export pumps. BA re-uptake by enterocytes stimulates FGF-19 release into the portal blood, which inhibits BA synthesis. (B) Free fatty acids (FFA) derive from lipolysis in
adipose tissue and are actively taken up by various FA transporters under the control of insulin (Ins) and nuclear receptor signaling. Under physiologic conditions, the bulk of
FAs is oxidized intramitochondrially and provides ATP and acetyl-CoA for the tricarboxylic acid cycle (TCA). Triglycerides (TAGs) derived from de novo lipogenesis are either
stored in lipid droplets (LD) or packed into VLDL and exported into the blood stream. Acetyl-CoA for de novo lipogenesis is provided by the pyruvate dehydrogenase complex
(PDC), which catalyzes oxidation of pyruvate, the end product of glycolysis. (C) Under physiologic conditions, b-oxidation of short-, medium- and long-chain FAs (SCFA,MCFA,
LCFA) are degraded in mitochondria. Therefore, FAs are activated to acyl-CoA and shuttled across the mitochondrial membrane by carnitine palmitoyltransferase-1 (CPT1).
Malonyl-CoA, an intermediate of lipogenesis, inhibits CPT1 and thus FA oxidation in the mitochondria. With FA abundance and in the insulin resistant state, LCFA and very-
long-chain FAs (VLCFA) are oxidized in peroxisomes and the ER. This leads to an abundance of metabolites that induce formation of ROS and contribute to lipotoxicity. (D) In
NASH, increased peripheral lipolysis, upregulation of FA transporters, an increase in DNL, and a switch from mitochondrial b-oxidation to peroxisomal and x-oxidation
promote FA toxicity and the release of ROS. This leads to the induction of hepatocyte apoptosis, the invasion and activation of inﬂammatory cells, as well as ﬁbrogenesis.
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Fig. 2. Regulation of hepatic glucose metabolism. (A) After intestinal absorption, glucose (Glu) reaches the hepatocyte via the portal vein. The insulin-independent
glucose transporter 2 (GLUT2) shuttles Glu across the membrane. Abundance of glucose induces conformational changes of the glucokinase regulatory protein (GCKR),
which binds to glucokinase (GCK) and keeps it in the nucleus in the fasting state. GCK is then released into the cytosol and phosphorylates Glu to glucose-6-phosphate (Glu-
6-P); depending on the nutritional state, it serves as a substrate for glycolysis or glycogen synthesis, respectively. GCK is transcriptionally regulated by insulin and nuclear
receptor signaling. (B) Glu-6-P is a central intermediate in the hepatic glucose metabolism. It is degraded during glycolysis, which provides energy in the form of two ATP
and two NADH molecules per glucose molecule. The product pyruvate is further decarboxylized to acetyl-CoA, which enters the intramitochondrial tricarboxylic acid cycle
(TCA). Alternatively, Glu-6-P is degraded in the pentose-phosphate shunt, which provides NADPH, a co-substrate for DNL. Acetyl-CoA is an important product of the TCA,
linking glucose and lipid metabolism, as it is the substrate for DNL (Fig. 1). Gluconeogenesis and glycogenolysis provide Glu-6-P as a substrate for glucose synthesis in the
fasting state. Glucogenolysis is catalyzed by glycogen phosphorylase, activated by AMP, and repressed by insulin. The key enzyme in gluconeogenesis is PEPCK, which is
repressed by insulin signaling via Akt-mediated FoxO phosphorylation and activated by PPARa.
Reviewactivity, which has also been identiﬁed to facilitate FA uptake
[34,35]. Besides the fact that the regulation of FATP activity is
generally complex, the individual contribution of these FATPs to
FA uptake has not been entirely clariﬁed yet. Nevertheless, sig-
naling via PPARa again predominantly regulates the transcription
of these transport proteins as combined with hormonal regula-
tion via insulin and leptin [30,36].
Macroautophagy
Autophagy has recently been implied to play a role in hepatic lipid
homeostasis [37]. As a lysosomal pathway, it recycles dispensable
cellular constituents into important energy sources during the
fasting state [38]. Recent animal studies revealed that autophagy
is a key process in hepatic lipolysis and lipid droplet degradation
[10,39]. As mentioned above, lysosomes process chylomicron
remnants as well as TAGs that accumulate during hepatic lipogen-956 Journal of Hepatology 201esis. During starvation, macroautophagy leads to the fusion of
lysosomes and lipid droplets into autophagosomes, which are
then degraded; FAs are thus released and can be catabolized via
b-oxidation. Starvation leads to repression of the so-called mam-
malian target of rapamycin (mTOR), an insulin downstream target
that inhibits autophagy. Interestingly, rapamycin treatment also
downregulates SREBP-1c in primary hepatocytes, which suggests
an effect of rapamycin, independent of mTOR, on the activity of
forkhead box protein O (FoxO) [40]. Long-term repression of
autophagy is accounted for by insulin action, and Akt mediated
de-phosphorylation of FoxO, a transcriptional activator of autoph-
agy related genes (ATGs). Indeed, FoxO simultaneously represses
SREBP-1c activation and thus DNL. Thus, insulin receptor activa-
tion induces DNL and represses autophagy-mediated lipid droplet
degradation, both short- and long-term, via two distinct mecha-
nisms. However, in the insulin-resistant state and in obesity per
se, hepatic mTOR is over-activated and calpain, a repressor of2 vol. 56 j 952–964
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ATGs, is induced [9]. Despite FoxO activation in IR, mTOR and cal-
pain activation account for the repression of hepatic autophagy in
obese individuals.
Fatty acid oxidation
Oxidation of FAs occurswithinmitochondria, peroxisomes and the
ER, and facilitates degradation of activated FAs to acetyl-CoA. It is a
rapid and effectiveway of energy allocation since, for example, the
oxidation of one molecule of palmitate produces up to 129 ATP
equivalents [41]. FAs are activated by acyl-CoA-synthetase to
acyl-CoA in the cytosol. This process is indispensable for enabling
FAs to cross membranes and enter organelles. While short- and
medium-chain FAs pass the mitochondrial membrane without
activation, activated long-chain fatty acids (LCFAs) are shuttled
across the membrane via carnitine palmitoyltransferase-1
(CPT1). Malonyl-CoA, an early intermediate of DNL that accumu-
lates upon insulin receptor activation, is an allosteric inhibitor of
CPT1 [42]. Thus, in the fed state, FA oxidation is inhibited and
DNL-promoted, allowing for storage and distribution of lipids
[43]. In general, short-, medium- and LCFAs are oxidized within
mitochondria (b-oxidation), while toxic, very-long-chain FAs are
oxidized within peroxisomes (Fig. 1C). In diabetes or FA overload,
cytochrome P450 (a.k.a. CYP4A)-dependent x-oxidation of LCFAs
occurs in the ER and induces ROS and lipid peroxidation [44]. Dur-
ing the process of b-oxidation, electrons are indirectly donated to
the electron transport chain to drive ATP synthesis. Acetyl-CoA
can be further processed via the tricarboxylic acid cycle (TCA) or,
in the case of FA abundance, be converted into ketone bodies
[45]. PPARa and insulin signaling are again involved in the regula-
tion of FA oxidation and the formation of ketone bodies via tran-
scriptional regulation of mitochondrial HMG-CoA synthase.
Interestingly, succinyl-CoA, an intermediate of the TCA, inactivates
mitochondrial HMG-CoA synthase by succinylation, which once
more intercalates glucose- and lipidmetabolism [46]. For a simpli-
ﬁed overview of key metabolic pathways in hepatocellular lipid
homeostasis, see Fig. 1B.
Key Points 2
• Insulin activates DNL via PI3K-mediated FAS expression
• SREBP-1c and ChREBP transcriptionally activate FAS 
and ACC as well as VLDL assembly
• Insulin represses peripheral lipolysis and liberation of 
FFAs from adipocytes 
• Insulin represses autophagy via activation of mTOR and 
repression of FoxO phosphorylation
• Insulin represses FA oxidationHepatic glucose metabolism
Hepatocyte glucose uptake
In the postprandial state, blood glucose is taken up by the hepa-
tocyte via the glucose transporter type 2 (GLUT2) – a membrane-
bound transporter with high capacity and low afﬁnity for glucose.Journal of Hepatology 201In contrast to GLUT4, which is expressed by muscle and adipose
tissue, the expression and activity of GLUT2 is independent of
insulin signaling. In pancreatic islet cells, GLUT2 is thus also
referred to as a ‘‘glucose sensor’’ [47]. Once taken up by the hepa-
tocyte, glucose is phosphorylated to glucose-6-phosphate by liver
glucokinase (L-GCK; Fig. 2), the rate limiting enzyme for hepatic
glucose utilization [48]. In contrast to other hexokinases, GCK
(syn.: hexokinase IV) is not inhibited by its product, which allows
for postprandial glycogen storage within the hepatocyte. In the
fasting state, L-GCK is inactive and bound to glucokinase regula-
tory protein (GCKR) within the nucleus. Post-prandial glucose
abundance and insulin-action synergistically cause rapid dissoci-
ation of L-GCK from GCKR and translocation to the cytoplasm
[49]. L-GCK is transcriptionally regulated by SREBP-1c, hepatic
nuclear factor-4-alpha (HNF4a), hepatic nuclear factor 6
(HNF6), FoxO1, and upstream stimulatory factor 1 (USF1) (see
Fig. 2A). Indeed, mutations in the GCK gene have been associated
with IR and the pathogenesis of maturity-onset diabetes of the
young (MODY) in several studies [50,51].Glycolysis and glycogen synthesis
Glucose-6-phosphate is either further processed in glycolysis or
utilized for glycogen synthesis, depending on the systemic meta-
bolic state. Glycolysis, a ten-step process, metabolizes glucose to
pyruvate with a net gain of two ATP and two NADHmolecules per
glucose molecule. Glycolysis is regulated by L-GCK, which pro-
vides glucose-6-phosphate, phosphofructokinase, which is inhib-
ited by its product fructose-1,6-bisphosphate, AMP and pyruvate-
kinase (PK), the ﬁnal step in glycolysis. PK is activated by its sub-
strate and inhibited by abundance of ATP. Insulin, epinephrine,
and glucagon also regulate PK via the PI3K pathway and ChREBP
induces transcription of PK in the presence of glucose [23]. Pyru-
vate is further decarboxylized to acetyl-CoA and then processed
in the TCA or utilized for DNL. The pentose phosphate pathway
is an alternative way for degradation of glucose-6-phosphate in
hepatocytes, which provides the cell with NADPH, an important
antioxidant and co-substrate for DNL and cholesterol synthesis.
In hepatocellular carcinoma (HCC), glycolytic activity is dramati-
cally upregulated and associated with increased hexokinase 2
activity and expression of GLUT1, leading to altered glucose uti-
lization, which has therapeutic and diagnostic implications (for
the so-called Warburg effect, Fig. 3B and C) [52].
Glycogen synthesis is catalyzed by glycogen synthase (GS)
after conversion of glucose-6-phosphate to UDP-glucose [53].
GS is regulated by the allosteric activator glucose-6-phosphate
and is inactive in the phosphorylated state. Glycogen synthase
kinase 3 (GSK3) phosphorylates GS and is a downstream target
of Akt/PI3K and thus insulin signaling. GSK3 is a multifunctional
kinase, involved in cell senescence, apoptosis and lipid metabo-
lism via phosphorylation of SREBP-1c [54]. Other protein kinases
that phosphorylate GS are AMP-activated protein kinase (AMPK)
and protein kinase A (PKA). Insulin activates glycogen synthesis
via repression of PKA. GS synthesizes the glycogen polymer,
which is further branched by a branching enzyme.Glycogenolysis and gluconeogenesis
In the fasting state, the liver supplies the body with energy by
breaking down glycogen, and following prolonged fasting by glu-
coneogenesis [55]. Glycogen breakdown is catalyzed by glycogen2 vol. 56 j 952–964 957
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Fig. 3. Hepatic lipid and glucose metabolism in HCC. (A) Mediators of NAFLD progression also contribute to carcinogenesis in the liver. In general, obesity and diabetes
have been identiﬁed as risk factors for cancer development as well as inﬂammation. Cirrhosis is a precancerous condition and, in fact, most HCCs derive from cirrhotic livers.
Important mediators of insulin resistance and lipotoxicity also induce dysplasia and carcinogenesis. This ﬁgure gives a brief overview of different cytokines and cell
signaling pathways involved in HCC development. (B) Expression of GLUT1 in hepatoma cells leads to increased hepatic glucose utilization. Glucokinase is downregulated,
but hexokinase 2 (HK2) is now expressed and phosphorylates glucose with a higher afﬁnity. Aerobic glycolysis leads to a rapid, but rather ineffective energy supply to the
proliferating cancer cell. However, this process, referred to as the Warburg effect, facilitates uptake and de novo synthesis of nutrients (nucleotides, amino acids, lipids),
available for cell proliferation and tumor growth. (C) Clinically, this effect is utilized in PET diagnostics. An increase in cancer cell glucose uptake, as visualized by FDG
PET/CT, acts as an important tool in HCC diagnostics.
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phosphorylase (PYGL), which cleaves glucose from the glycogen
polymer and produces glucose-1-phosphate, which is converted
to glucose-6-phosphate by phosphoglucomutase. A debranching
enzyme cleaves the last four glucose monomers. PYGL is regu-
lated through allosteric activation by AMP and via phosphoryla-
tion by PKA, which is inhibited by insulin.Key Points 3
• NRs are highly conserved ligand-activated transcription 
either endogenous (bile acids; fatty acids; hormones; 
vitamins) or exogenous (drugs; xenobiotic toxins), 
and induce conformational changes affecting the 
transcriptional activation of downstream targets [64, 65]. 
Most NRs heterodimerize with the retinoid-X-receptor. 
Table 1 sketches the most abundant NRs in the liver, 
their ligands, and their roles in hepatic lipid and glucose 
homeostasis
• PPARα is the most abundant PPAR in the healthy 
liver. It regulates FA oxidation and uptake as well as 
gluconeogenesis (PEPCK) and glycogen synthesis 
(GSK3; GS) (see above). Moreover, PPARα activation 
hepatocyte proliferation via induction of microRNA 
let7c-signaling cascades [66, 67]. In mouse models, 
but not in humans, activation of PPARα induces hepatic 
carcinogenesis, which is in part explained by ROS 
production [68, 69] and induction of  microRNA let7c 
that degrades the c-myc oncogene. Initially an orphan 
the therapy of hypertriglyceridemia – and recently a 
ligand [21], produced by the enzyme FAS, which in turn 
is activated by PPARα and other NRs. Emphasizing the 
cross-talk between NRs, FXR and LXR are known to 
activate PPARα signaling while VDR appears to repress 
PPARα signaling [58, 70, 71]. Post-transcriptionally, 
PPARα protein expression is repressed by microRNA 
10b, which is associated with metastasis formation in a 
variety of cancers [72] 
• PPARγ is mainly expressed in adipocytes, where it 
promotes lipid uptake and TAG storage by upregulation 
of the LDL receptor and CD36/FAT, induces stearoyl-
CoA-desaturase-1 (SCD1), increases insulin sensitivity 
by induction of GLUT4, and decreases TNFα levels and 
thus systemic IR [73]. In NAFLD, PPARγ is upregulated 
PPARγ KO mice are 
protected from diet-induced steatosis [74, 75]. PPARγ 
signaling [76]. Recently, activation of PPARδ has been 
shown to reduce hepatic lipogenesis by suppression of 
SREPB-1c [76, 77] in addition to increasing the hepatic 
glucose catabolism as well as muscular oxidation
• The PPARγ co-activator-1α (PGC1α) is a 
transcriptional co-activator that regulates mitochondrial 
biology and energy homeostasis [78]. PGC1α is 
induced by fasting and activates FA oxidation and 
gluconeogenesis via induction of PPARα, FoxO1 and 
HNF-4α [79]. Sirtuin 1 (SIRT1) deacetylates PGC1α and 
thus regulates its activity [80]
factors. Specific ligands of most NRs are known, are
has anti-inflammatory effects and (in mice) induces
NR, PPARα is known to be the receptor for fibrates in
diacylglycerol has been identified as an endogeneous
in liver tissue, and liver-specific
has anti-inflammatory features as it represses NFκB
Journal of Hepatology 201Hepatic gluconeogenesis occurs during prolonged fasting epi-
sodes and begins intramitochondrially by the induction of pyru-
vate carboxylase in abundance of acetyl-CoA. Interestingly,
inhibition of hepatic CPT-1 and thus mitochondrial fatty acid oxi-
dation signiﬁcantly represses hepatic gluconeogenesis in mice
[56]. Gluconeogenesis is further regulated via allosteric and• FXR, the bile acid receptor and its downstream target, 
small heterodimer partner (SHP), have recently 
metabolism as BA administration lowers blood 
lipids and the TAGs hepatic content. This effect is 
partially reversed in SHP KO mice and is mediated 
by transcriptional repression of SREBP-1c [81]. Thus, 
FXR represses hepatic DNL and VLDL export. FXR KO 
mice develop hepatic steatosis, and treatment with FXR 
agonist attenuates hepatic steatosis in mice when fed a 
that induces steatosis and oxidative stress, rather than 
insulin resistance [82, 83]. Other studies also revealed 
that FXR agonists improve IR [64, 84]. In the intestine, 
factors 15 (mouse) and 19 (human) (FGF15/19), which 
activates hepatic FA oxidation and insulin response 
via activation of the FGF receptor 4 [85, 86]. BAs have 
additional effects on lipid and glucose metabolisms via 
a G-protein-coupled receptor (TGR5/GBAR), which 
regulates energy expenditure in brown adipose tissue 
(and possibly skeletal muscle), and promotes intestinal 
GLP-1 secretion [87]. Thus, BAs may now be viewed 
as enterohepatic hormones that circulate with absorbed 
• Natural ligands of LXR are hydroxysterols. LXRα is 
expressed primarily in hepatocytes, adipose tissue 
and macrophages, whereas LXRβ is expressed 
ubiquitously [88]. LXR regulates SREBP-1c, FAS 
and SCD-1 expression and LXRα agonist treatment 
leads to hypertriglyceremia secondary to induction of 
hepatic lipogenesis [89]. LXR increases hepatic glucose 
uptake by induction of GLUT4 expression and has 
immune response [90, 91]
• LRH1 has recently been implied as a novel NR in BA 
homeostasis by transcriptional activation of Cyp7A1 
[92]. Interestingly, LRH1 activation by dilauroyl 
phosphatidylcholine improves the hepatic insulin 
response and hepatic lipid accumulation in high fat diet-
fed mice [93]. Accordingly, SREBP-1c, FAS and SCD-1 
mRNA levels were downregulated in the treatment group
• The VDR
Recent studies have shown that vitamin D 
supplementation protects mice from diet-induced 
steatosis and VDR KO mice spontaneously develop 
hepatic steatosis [94, 95]. Polymorphisms in VDR 
are associated with HCC development in patients 
with alcoholic cirrhosis, and VDR activation acts 
antiproliferative effects [96, 97]. In HCV patients, low 
and the VDR regulates T-cell activation [97, 98]
been identified to play a central role in hepatic lipid
methionine- and choline- deficient diet (MCD), a model
FXR activation induces secretion of fibroblast growth
dietary lipids and fine-tune their metabolism
anti-inflammatory attributes as it modulates the innate
is a novel target in the field of hepatology.
vitamin D levels are associated with fibrosis progression,
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transcriptional activation of phosphoenolpyruvate carboxykinase
(PEPCK), fructose-1,6-bisphosphatase and glucose-6-phosphatase
(G6Pase). Overexpression of PEPCK promotes IR in mice [57].
Insulin action represses PEPCK expression via Akt-mediated
FoxO1 phosphorylation. This pathway is repressed by activation
of PPARa signaling-mediated induction of the pseudokinase trib-
bles-homologue 3 (TRB3), and TRB3 expression is associated with
IR in patients [58,59]. Other NRs (PGC1a, FXR), glucagon and glu-
cocorticoids also mediate expression of PEPCK and G6Pase
[55,60]. FoxO1, a transcriptional activator of PEPCK and G6Pase,
is both directly and indirectly activated by PGC1a, HNF4a, CREBP
and PPARa [61]. PEPCK knock-out mice not only show decreased
gluconeogenesis, but more importantly a decreased removal of
TCA anions, which causes hepatic TAG accumulation and steato-
sis [62]. In mice, PEPCK overexpression in the striated muscle
interestingly leads to longevity and an impressive increase in
muscle strength and endurance; this phenotype is partially
explained by an optimized mitochondrial oxidation of TAG [63].
These processes again demonstrate the close inter-relation
between gluconeogenesis and hepatic lipid metabolism (Fig. 2B).Hepatic lipid and glucose metabolism in liver injury
Serum FFA levels correlate with hepatocyte apoptosis and FAs
were found to activate death receptor-mediated apoptosis
[64,65]. On the other hand, high glucose concentrations induce
apoptosis in hepatoma cell lines, and the HOMA score is associ-
ated with hepatocyte apoptosis in NAFLD patients [66,67]. These
observations indicate that hepatocyte apoptosis due to an imbal-
ance in cell metabolism has clinical implications for NAFLD, liver
regeneration, as well as ﬁbrogenesis and carcinogenesis. The
effects of systemic IR on liver injury via induction of TNFa are dis-
cussed in detail below. Intrahepatic fat deposition and obesity
decrease hepatic blood ﬂow by direct compression and systemic
hypercatecholemia and thus inhibit mitochondrial function and
cause formation of ROS, which induces Kupffer cell activation,
hepatic inﬂammation, and hepatocyte apoptosis [68]. Interest-
ingly, mitochondrial stress may be partially reversed by treat-
ment with insulin-like-growth factor 1 (IGF-1) and PPARc
agonists [69,70]. Alcohol-fed PPARa knock-out mice develop a
phenotype that mimics alcoholic liver disease in humans, which
is linked to ROS accumulation [71]. Overexpression studies iden-
tiﬁed that the expression of PEPCK links mitochondrial dysfunc-
tion with the ER stress response [72].
As mitochondria are the main organelles in energy combus-
tion, the ER is the major site of protein folding and trafﬁcking.
Recently, activation of the unfolded protein response (UPR)
within the ER has been implied as a key modulator of cellular
inﬂammation and is linked to IR, lipid and glucose metabolism
[73]. Three membrane-bound proteins regulate the UPR within
the ER; PKR-like eukaryotic initiation factor 2a kinase (PERK),
inositol-requiring enzyme 1 (IRE1), and activating transcription
factor-6 (ATF6). The protein kinase PERK affects transcriptional
regulation of rRNA, which activates NFjB and ATF4 signaling.
NFjB regulates inﬂammatory signaling (IL-6, TNFa), and ATF4
regulates glucose metabolism [74,75]. SREBP-1c activation occurs
during ER stress and thus affects the lipid metabolism – and the
ER possibly regulates the number, composition and quality of
lipid droplets [76–78]. Furthermore, induction of the mTOR
pathway in obese individuals activates SREBP-1c, promotes ER960 Journal of Hepatology 201stress and inhibits autophagy, a novel pathway in the biology
of hepatic lipid droplets [79,80].NAFLD, insulin resistance and lipotoxicity
NAFLD represents the most prevalent liver disease in Western
societies. It presents with a wide spectrum ranging from simple
steatosis or non-alcoholic fatty liver (NAFL) to fully developed
NASH with or without ﬁbrosis. NASH can progress to ﬁbrosis with
an increased risk to develop end-stage liver disease or hepatocel-
lular carcinoma (HCC) [1]. Hepatic steatosis is deﬁned as an intra-
hepatic accumulation of TAGs. In parallel, abundant FAs cause
lipotoxicity via the induction of ROS release, which causes inﬂam-
mation, apoptosis, and thus the progression to NASH and ﬁbro-
genesis [81]. As described above, most FAs derive from the
circulation secondary to increased lipolysis in adipose tissue as
well as DNL [3].
Obesity increases the TNFa production in adipocytes, which
facilitates adipocyte IR and increases lipolysis rate [82]. Thus,
the circulating FFA pool is increased in obese individuals and
accounts for the majority of liver lipids in NAFLD [13]. As men-
tioned, uptake of FFAs into the hepatocyte is facilitated by a vari-
ety of FATPs; several studies found an upregulation of these
transporters in NAFLD and NASH as well as a correlation with dis-
ease severity [65,83,84]. Fifteen percent of the lipid content
within the steatotic liver derives from an increased dietary intake
of lipids [3]. DNL may account for up to 30% of TAGs in steatotic
livers, a mechanism that involves dysregulation in SREBP-1c- and
FoxO-mediated hepatic insulin signaling [4,85,86]. Since autoph-
agy-related genes are transcriptionally activated by FoxO and
insulin action modulates autophagy, recent studies showed that
macroautophagy is dysregulated in the metabolic syndrome
[87]. Accordingly, in conditional atg7-knockout mice, Singh
et al. observed an increase in hepatic lipid accumulation, and in
genetic and dietary mouse models for obesity and hepatic steato-
sis, autophagy-related genes were downregulated [10,12].
The long-lasting paradigm claiming TAG accumulation to be
the ‘‘ﬁrst hit‘‘ that predisposes to further liver damage in the
pathogenesis of NASH has recently been replaced by a more com-
plex model as emerging evidence points to FAs and their metab-
olites as the true lipotoxic agents [7]. Interestingly, lipid
accumulation and altered composition of phospholipids within
ER membranes further promotes ER stress and IR in obese mice
[8]. Cytosolic TAGs are thus now considered to be inert and, in
fact, lipid droplet accumulation has recently been found to be
hepatoprotective [88]. Notably, genetic deletion of DGAT2
(responsible for TAG formation) increases hepatocellular injury
in MCD-fed mice despite a reduction in the content of hepatocel-
lular TAGs [89]. However, TAG accumulation and lipid droplet
formation accompany and parallel pathophysiologic mechanisms
in NASH. FFAs are thus now in the focus of basic research – and
FAs as well as acyl-CoA and acetyl-CoA have been identiﬁed as
potential causes of lipotoxicity [90]. FAs have been found to acti-
vate Toll-like receptors and initiate the extrinsic apoptosis cas-
cade [91,92]. FAs also interfere with NR signaling, which might
additionally inﬂuence the extent of hepatocyte damage and fur-
ther promote IR and ER stress [93,94]. Accordingly, b-oxidation
of LCFA within peroxisomes and x-oxidation within the ER are
upregulated in NASH and contribute to lipotoxicity and ROS
formation [95,96]. This might be secondary to inhibition of2 vol. 56 j 952–964
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mitochondrial b-oxidation due to an accumulation of malonyl-
CoA and the inhibition of CPT1 [3,97,98]. In fact, recent studies
indicate that activation of mitochondrial FA oxidation protects
from steatosis and IR [99,100]. As mentioned above, DAGs and
ceramides might as well contribute to hepatocyte damage and
IR in NAFLD [7].
These stressors induce a variety of intracellular and paracrine
mechanisms that may promote hepatocellular damage. FAs
induce the production of TNFa, and hepatic TNF receptor expres-
sion correlates with the disease severity in NAFLD [101]. TNF
receptor activation increases expression of SREBP-1c, which
induces hepatic lipogenesis and lipid accumulation [102]. As
TNFa-mediated effects are antagonized by adiponectin, adipo-
nectin receptors are actually downregulated in NASH [103]. TNFa
activation is further paralleled by death-receptor expression,
which facilitates activation of the extrinsic apoptosis cascade.
Apoptosis indeed is the predominant form of hepatocellular
injury in NASH [64,104]. In fact, apoptotic activity within the dis-
eased liver correlates with disease severity and thus cleaved cyto-
keratin-18 fragments in the serum of NAFLD could effectively be
utilized as surrogate markers for the progression of NAFLD [105].
As previously mentioned, FA accumulation also leads to induction
of ER stress and ROS formation, which again promotes hepatic
injury [1,106].
In summary, while hepatic TAG accumulation seems to be a
benign symptom of hepatic steatosis, FA metabolites contribute
to the progression of NAFLD to NASH. IR promotes the recruit-
ment of FFAs from the serum pool as well as intrahepatic FA
accumulation, which induces apoptosis and ROS formation. FAs
themselves also promote hepatic IR via TNF receptor activation,
hence indicating a vicious circle of lipid accumulation and IR as
a crucial mechanism in the pathogenesis of NASH (Fig. 1D).Acute liver injury and regeneration
Injured livers produce cytokine signals that trigger adipose tissue
to release FAs into the circulation. Indeed, in the acute response,
hepatocytes initiate the transcription of lipogenic genes and accu-
mulate TAGs in intracellular lipid droplets. In liver regeneration
(e.g., after partial hepatectomy (PHx)), lipid droplet formation is
essential to propagate the proliferative response by sufﬁciently
supplying the organ’s energy household. Droplet-stored lipids
are also used for synthesizing new lipoproteins, bile acids, and
entire membranes [107,108]. As previously mentioned, emerging
data supports a close connection between BA and FA metabolism.
In this context, FATP-5 has also been suggested to participate in BA
metabolism as a bile acid-CoA ligase [109,110]. FATP-5 is
expressedpreferentially towards the space ofDisse and closely fol-
lows the hepatic sinusoids [109] where FAs and BAs are absorbed
from the enterohepatic circulation. Intriguingly, it has been
recently shown that elevated BAs accelerate liver regeneration
after PHx by bile acid receptor (FXR)-dependent signals [107,111].
Autophagy in acute liver injury might to a certain degree act
hepatoprotectively as it rapidly supplies the hepatocyte with
energy. However, hyperactivation of autophagy induces cell
death, and the necrosis rate is actually a predictor of liver failure
[9,112]. Furthermore, as we previously elucidated key processes
in the interplay between adipose tissue and the liver, adiponectin
was identiﬁed as an important mediator of STAT3 signaling in the
regenerating liver [113,114].Journal of Hepatology 201Liver cancer
Emerging data supports a role for lipid and glucose metabolism
in hepatocellular carcinogenesis [115]. First of all, the increase
in the prevalence of NAFLD is closely associated with the devel-
opment of cirrhosis and NASH-related HCC [116]. Accordingly,
NASH might account for the majority of HCC in the context of a
cryptogenic cirrhosis [117]. Obesity and diabetes have been iden-
tiﬁed as independent risk factors for developing HCC (Fig. 3A)
[118,119]. Several studies could recently dissect the effects of
individual confounders of the metabolic syndrome and clearly
demonstrate a signiﬁcant risk for NAFLD patients to develop
HCC [120]. Intriguingly, HCC in NAFLD not only arises from cir-
rhotic tissue; this might imply a special role for lipid metabolism
and lipotoxicity in the carcinogenesis within this cohort [121].
To date however, the vast majority of HCC cases arise from
patients with cirrhosis secondary to chronic HBV or HCV infection
[122]. Wu et al. recently identiﬁed various alterations in multiple
genes involved in hepatic lipogenesis, FA oxidation, and TAG
metabolism in tumors derived from HCV patients compared to
HCV-positive control patients [123]. Mechanistically, mediators
and signaling cascades involved in the hepatic IR and the regula-
tion of hepatic lipid metabolism are in the focus of HCC research.
Several studies identiﬁed the insulin receptor downstream targets
PI3-kinase/Akt and IRS to be activated in HCC when compared to
surrounding healthy tissue, which mediates GSK3b phosphoryla-
tion andmTOR activation [124]. Thesemediators not only interact
with b-catenin signaling, but also with autophagy and glycogen
synthesis. In fact, knock-out mice with speciﬁc deletions in
autophagy-related genes show spontaneous development of
hepatocellular dysplasia [125]. As pointed out before, TNFa
induces hepatic IR and thus promotes lipid accumulation. TNF
and IL-6 signaling is also involved in the activation of the JAK/STAT
andERKpathways; bothmediators are crucial for thedevelopment
of obesity induced-HCC in a rodent model [126]. On the other
hand, JAK/STAT signaling is closely linked to, and partially modu-
lated by, the adipocytokines leptin and adiponectin [127].
NRs play a crucial role in hepatic lipid and glucose homeosta-
sis (see also above) and are important mediators of hepatic carci-
nogenesis. PPARamediates hepatic FA-oxidation and transport as
well as Akt phosphorylation via its downstream target TRB-3
[15]. PPARa agonists promote carcinogenesis in a rodent model
for HCV infection [128]. Interestingly, PPARa agonists not only
interfere with the binding of PPARa to SREBP-1c, but also with
STAT3 in hepatoma cell lines, thus indicating a potential mecha-
nism for its carcinogenic properties [129]. In contrast, PPARc ago-
nists prevent NAFLD progression and, more interestingly, were in
some studies described to act antineoplastically [130,131]. Nota-
bly, the majority of mechanistical data in hepatic carcinogenesis
derives from hepatoma cell lines and murine models that are
only of limited value for the elucidation of hepatic carcinogenesis
in humans.Conclusions
Hepatic lipid and glucose metabolism are closely interrelated
with inﬂammatory, proliferative and apoptotic signaling within
the liver. In the liver, these catabolic and anabolic pathways
can hardly be separated. They share intermediate metabolites
and receptor signaling, and go hand in hand in the pathogenesis2 vol. 56 j 952–964 961
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of the most common liver diseases. Intriguingly, the case that
these metabolic pathways are also involved in cell proliferation,
regeneration and carcinogenesis implies potent future therapeu-
tic approaches for life-threatening diseases. The enhanced under-
standing of these basic mechanisms is thus imperative as we
witness a rising prevalence of obesity and the metabolic
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